Full Length Research Paper
References
|
Alam S, Ueki K, Nakagawa K (2009). Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiol. Endod. 107(1):22-29. crossref |
||||
|
Alexandra P, Courtney CK, Lisa D, Elaine L, Jonathan DA (2007). Patient adherence to osteoporosis medications. Drugs Aging 24(1):37-55. crossref |
||||
| Bancroft JD, Cook HC, Turner DR (1994). Manual of histological techniques and their diagnostic application. 2nd ed. USA: Churchill Livingstone. | ||||
| Bancroft JD, Gamble M (2002). Theory and practice of histological techniques. 5th ed. USA: Churchill Livingstone. | ||||
| Barnett RN, Skodan SB, Goldberg MH (1973). Performance of kits used for clinical chemistry analysis of calcium in the serum. Am. J. Clin. Pathol. 56 (6):836-845. | ||||
|
Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, de Vries F (2014). Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int. 25(4):1275-1283. crossref |
||||
|
Cramer J. A., Gold D. T. & Silverman S. L. et al (2007). Systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int. 18(8):1023-1031 crossref |
||||
| Daily JA, Ertingshausen G (1972). Direct method for determination of inorganic phosphate in serum with the centrifuge. Clin. Chem. 18:263. | ||||
| Fujita Y, Watanabe K, Uchikanbori S, Maki K (2011). Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats. Am. J. Orthod Dentofacial Orthop. Mar. 139(3):267-277. | ||||
| Garrett IR, Esparza J, Chen D, Zhao M, Gutierrez G, Escobedo A, Horn D, Mundy GR (2000): Statins mediate their effects on osteoblasts by inhibition of HMG-CoA reductase and ultimately BMP2. J. Bone Miner Res. 15(Suppl):s225. | ||||
|
Griffith JF, Wang YX, Zhou H, Kwong WH, Wong WT, Sun YL and Ahuja AT (2010). Reduced bone perfusion in osteoporosis: likely causes in an ovariectomy rat model. Radiology 254:739-746. crossref |
||||
|
Jadhav SB1, Jain GK (2006). Statins and osteoporosis: new role for old drugs. J. Pharm. Pharmacol. 58(1):3-18. crossref |
||||
| Yeh JH, Chen HJ, Chen YK, Chiu HC, Kao CH (2014). Increased risk of osteoporosis in patients with myasthenia gravis: A population-based cohort study neurology. 83:1075-1079. | ||||
|
John MT, Seeman E (2007). New mechanisms and targets in the treatment of bone fragility. Clin. Sci.112:77–91. crossref |
||||
|
Johnell O., Kanis J. A. (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int. 17(12):1726-1733. crossref |
||||
|
La Rosa JC, He J, Vupputuri S (1999). Effect of statins on risk of coronary disease: a meta- analysis of randomized controlled trials. JAMA 282(24):2340-2346. crossref |
||||
|
Lu H, Yuan G, Yin Z, Dai S, Jia R, Xu J, Lv C (2014). Effects of subchronic exposure to lead acetate and cadmium chloride on rat's bone: Ca and Pi contents, bone density, and histopathological evaluation. Int. J. Clin. Exp. Pathol. 7:640-647. Pubmed |
||||
|
Mazziotti G, Porcelli T, Mormando M (2011). Vertebral fractures in males with prolactinoma. Endocrine 39(3):288-293. crossref |
||||
|
McCombs JS, Thiebaud P, McLaughlin-Miley C (2004). Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287. crossref |
||||
|
Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000). HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 283:3205-3210 crossref |
||||
|
Mundy G, Garrett R, Harris S (1999). Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949. crossref |
||||
|
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999). Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104:1363-1374. crossref |
||||
|
Pobeha P, Ukropec J, Skyba P, Ukropcova B, Joppa P, Kurdiova T, Javorsky M, Klimes I, Tkac I, Gasperikova D, Tkacova R. (2011). Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. Bone 48(5):1008-1014. crossref |
||||
|
Rejnmark L1, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L (2004). Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res. 19(5):737-744. crossref |
||||
|
Ruan F, Zheng Q, Wang J (2012) Mechanisms of bone anabolism regulated by statins. Biosci. Rep. 32(6):511-5119. crossref |
||||
|
Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikama S (2000). Compactin and simvastatin, but not pravastatin, induce bone morpho- genetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271:688-692. crossref |
||||
|
Tsartsalis AN, Dokos C, Kaiafa GD, et al (2012) Statins, bone formation and osteoporosis: hope or hype? Hormones (Athens) 11:126-139. crossref |
||||
|
Wang L, Duan G, Lu Y, Pang S, Huang X, Jiang Q, Dang N (2013). The Effect of Simvastatin on Glucose Homeostasis in Streptozotocin Induced Type 2 Diabetic Rats. J. Diabetes Res. 5 pp. crossref |
||||
|
Wang PS, Solomon DH, Mogun H, Avorn J (2000). HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 283:3211-3216. crossref |
||||
|
Yin H, Shi ZG, Yu YS, Hu J, Wang R, Luan ZP, Guo DH (2012). Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats. Eur. J. Pharmacol. 674(2-3):200-206. crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
